Compare SPRO & SOTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPRO | SOTK |
|---|---|---|
| Founded | 2013 | 1975 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.0M | 72.1M |
| IPO Year | 2017 | 1995 |
| Metric | SPRO | SOTK |
|---|---|---|
| Price | $1.10 | $6.16 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | $5.00 | ★ $8.50 |
| AVG Volume (30 Days) | ★ 839.8K | 134.1K |
| Earning Date | 11-12-2026 | 10-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 111.81 | 37.50 |
| EPS | N/A | ★ 0.07 |
| Revenue | ★ $66,802,000.00 | $20,909,315.00 |
| Revenue This Year | N/A | $2.59 |
| Revenue Next Year | N/A | $23.41 |
| P/E Ratio | ★ N/A | $87.21 |
| Revenue Growth | ★ 39.24 | 1.97 |
| 52 Week Low | $1.08 | $3.40 |
| 52 Week High | $3.08 | $7.48 |
| Indicator | SPRO | SOTK |
|---|---|---|
| Relative Strength Index (RSI) | 41.51 | 53.94 |
| Support Level | $1.10 | $4.07 |
| Resistance Level | $1.28 | $7.48 |
| Average True Range (ATR) | 0.06 | 0.68 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 2.50 | 47.89 |
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Sono-Tek Corp designs and manufactures ultrasonic coating systems for applying precise, thin film coatings to add functional properties, protect or strengthen surfaces on parts and components for the microelectronics/electronics, alternative energy, medical, industrial, and emerging research & development/other markets. The company designs and manufacture custom-engineered ultrasonic coating systems incorporating its patented technology, in combination with applications engineering knowledge, to assist its customers in achieving their desired coating solutions.